Skip to main content

Volume 7 Supplement 1

Practical guide for allergy and immunology in Canada

Reviews

Edited by Harold Kim, Richard Warrington and Wade Watson

Publication of this supplement has been supported by Merck, AstraZeneca, GlaxoSmithKline, Graceway Pharmaceuticals, Nycomed, Novartis, King Pharma, Omega, Anaphylaxis Canada and the Allergy/Asthma Information Association.

  1. In basic terms, the immune system has two lines of defense: innate immunity and adaptive immunity. Innate immunity is the first immunological, non-specific (antigen-independent) mechanism for fighting against ...

    Authors: Richard Warrington, Wade Watson, Harold L Kim and Francesca Romana Antonetti
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S1
  2. Asthma is the most common respiratory disorder in Canada. Despite significant improvement in the diagnosis and management of this disorder, the majority of Canadians with asthma remain poorly controlled. In mo...

    Authors: Harold Kim and Jorge Mazza
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S2
  3. Allergic rhinitis is a common disorder that is strongly linked to asthma and conjunctivitis. It is usually a long-standing condition that often goes undetected in the primary-care setting. The classic symptoms...

    Authors: Peter Small and Harold Kim
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S3
  4. Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life of affected individuals as well as their families. Although the pathogenesis of the disorder is not c...

    Authors: Wade Watson and Sandeep Kapur
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S4
  5. Allergen-specific immunotherapy is a potentially disease-modifying therapy that is effective for the treatment of allergic rhinitis/conjunctivitis, allergic asthma and stinging insect hypersensitivity. However...

    Authors: William Moote and Harold Kim
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S5
  6. Anaphylaxis is an acute, potentially fatal systemic reaction with varied mechanisms and clinical presentations. Although prompt recognition and treatment of anaphylaxis are imperative, both patients and health...

    Authors: Harold Kim and David Fischer
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S6
  7. Food allergy is defined as an adverse immunologic response to a dietary protein. Food-related reactions are associated with a broad array of signs and symptoms that may involve many bodily systems including th...

    Authors: Susan Waserman and Wade Watson
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S7
  8. Eosinophilic esophagitis (EoE) is an atopic condition of the esophagus that has become increasingly recognized over the last decade. Diagnosis of the disorder is dependent on the patient’s clinical manifestati...

    Authors: Stuart Carr and Wade Watson
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S8
  9. Urticaria (hives) is a common disorder that often presents with angioedema (swelling that occurs beneath the skin). It is generally classified as acute, chronic or physical. Second-generation, non-sedating H1-...

    Authors: Amin Kanani, Robert Schellenberg and Richard Warrington
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S9
  10. Drug allergy encompasses a spectrum of immunologically-mediated hypersensitivity reactions with varying mechanisms and clinical presentations. This type of adverse drug reaction (ADR) not only affects patient ...

    Authors: Richard Warrington and Fanny Silviu-Dan
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S10
  11. Primary immunodeficiency disorder (PID) refers to a heterogeneous group of over 130 disorders that result from defects in immune system development and/or function. PIDs are broadly classified as disorders of ...

    Authors: Christine McCusker and Richard Warrington
    Citation: Allergy, Asthma & Clinical Immunology 2011 7(Suppl 1):S11

The official journal of CSACI

Annual Journal Metrics

  • 2022 Citation Impact
    2.7 - 2-year Impact Factor
    3.4 - 5-year Impact Factor
    0.989 - SNIP (Source Normalized Impact per Paper)
    0.634 - SJR (SCImago Journal Rank)

    2023 Speed
    19 days submission to first editorial decision for all manuscripts (Median)
    140 days submission to accept (Median)

    2023 Usage 
    1,545,686 downloads
    2,123 Altmetric mentions